Where is CYDY stock listed?

CytoDyn Inc. trades under the ticker CYDY on OTC.

How can I research CYDY's financials and filings?

Vantafin provides CytoDyn Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the CYDY profile.

CytoDyn Inc. (CYDY) stock profile

CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.

Key facts

Symbol	CYDY
Exchange	OTC
Sector	Healthcare
Industry	Biotechnology
CEO	Jacob Lalezari
Employees	9
Headquarters	Vancouver, WA, US
IPO	2006-12-13
Website	www.cytodyn.com

Explore CYDY on Vantafin

Frequently asked questions

What does CytoDyn Inc. (CYDY) do?: CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Where is CYDY stock listed?: CytoDyn Inc. trades under the ticker CYDY on OTC.
How can I research CYDY's financials and filings?: Vantafin provides CytoDyn Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the CYDY profile.

CytoDyn Inc. (CYDY) stock profile

Key facts

Symbol	CYDY
Exchange	OTC
Sector	Healthcare
Industry	Biotechnology
CEO	Jacob Lalezari
Employees	9
Headquarters	Vancouver, WA, US
IPO	2006-12-13
Website	www.cytodyn.com

Explore CYDY on Vantafin

Frequently asked questions

What does CytoDyn Inc. (CYDY) do?: CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
Where is CYDY stock listed?: CytoDyn Inc. trades under the ticker CYDY on OTC.
How can I research CYDY's financials and filings?: Vantafin provides CytoDyn Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the CYDY profile.